P-279 Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: phase 2 KEYNOTE-180 study

Por Manish, Shah, Jaafar, Bennouna, Lin, Shen, Peter, Enzinger, Qiao, Li, Ildiko, Csiki, Minori, Koshiji, Toshihiko, Doi
Publicado no Ann Oncol (2016)

P-280 Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarc...

Por Toshihiko, Doi, Jaafar, Bennouna, Lin, Shen, Peter, Enzinger, Ruixue, Wang, Ildiko, Csiki, Minori, Koshiji, Manish, Shah
Publicado no Ann Oncol (2016)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Por Yasuko Tada, Yosuke Togashi, Daisuke Kotani, Takeshi Kuwata, Eichi Sato, Akihito Kawazoe, Toshihiko Doi, Hisashi Wada, Hiroyoshi Nishikawa, Kohei Shitara
Publicado em 2018-10-01

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Por Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam
Publicado em 2019-03-01